Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease

Manisha Balwani, Catherine Breen, Gregory M. Enns, Patrick B. Deegan, Tomas Honzík, Simon Jones, John P. Kane, Vera Malinova, Reena Sharma, Eveline O. Stock, Vassili Valayannopoulos, J. Edmond Wraith, Jennifer Burg, Stephen Eckert, Eugene Schneider, Anthony G. Quinn – 24 January 2013 – Cholesteryl ester storage disease (CESD), an inherited deficiency of lysosomal acid lipase (LAL), is an underappreciated cause of progressive liver disease with no approved therapy. Presenting features include dyslipidemia, elevated transaminases, and hepatomegaly.

Thyroid hormone‐responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by Liver X receptor α through a sterol regulatory element‐binding protein 1c–dependent mechanism in mice

Jing Wu, Chunjiong Wang, Shuo Li, Sha Li, Wanyi Wang, Jing Li, Yujing Chi, Hang Yang, Xiaomu Kong, Yunfeng Zhou, Chengyan Dong, Fan Wang, Guoheng Xu, Jichun Yang, Jan‐Åke Gustafsson, Youfei Guan – 24 January 2013 – The protein, thyroid hormone‐responsive SPOT 14 homolog (Thrsp), has been reported to be a lipogenic gene in cultured hepatocytes, implicating an important role of Thrsp in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).

SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase‐3β/β‐catenin signaling

Juan Chen, Anthony W.H. Chan, Ka‐Fai To, Weixian Chen, Zhenzhen Zhang, Jihua Ren, Chunli Song, Yue‐Sun Cheung, Paul B.S. Lai, Suk‐Hang Cheng, Margaret H.L. Ng, Ailong Huang, Ben C.B. Ko – 24 January 2013 – Sirtuin 1 (SIRT1) has been implicated in telomere maintenance and the growth of hepatocellular carcinoma (HCC). Nevertheless, the role of other sirtuins in the pathogenesis of HCC remains elusive. We found that sirtuin 2 (SIRT2), another member of the sirtuin family, also contributes to cell motility and invasiveness of HCC.

The antimalarial ferroquine is an inhibitor of hepatitis C virus

Thibaut Vausselin, Noémie Calland, Sandrine Belouzard, Véronique Descamps, Florian Douam, François Helle, Catherine François, Dimitri Lavillette, Gilles Duverlie, Ahmed Wahid, Lucie Fénéant, Laurence Cocquerel, Yann Guérardel, Czeslaw Wychowski, Christophe Biot, Jean Dubuisson – 24 January 2013 – Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti‐HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)‐free treatments.

PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients

Heiner Wedemeyer, Donald Jensen, Robert Herring, Peter Ferenci, Mang‐Ming Ma, Stefan Zeuzem, Maribel Rodriguez‐Torres, Natalie Bzowej, Paul Pockros, John Vierling, David Ipe, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the PROPEL Investigators – 24 January 2013 – Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV).

Subscribe to